Evidence map›Paper›PMID 35103108›Full record

ArticleEngineering (Beijing, China)2022

Addressing the global challenges of COVID-19 and other pulmonary diseases with microfluidic technology.

Yuliang Xie, Ryan Becker, Michael Scott, Kayla Bean, Tony Jun Huang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Engineering (Beijing, China), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yuliang XieRoy J. Carver Department of Biomedical Engineering, College of Engineering, University of Iowa, Iowa City, IA, 52242, United States.
Ryan BeckerDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, 27710, United States.
Michael ScottRoy J. Carver Department of Biomedical Engineering, College of Engineering, University of Iowa, Iowa City, IA, 52242, United States.
Kayla BeanRoy J. Carver Department of Biomedical Engineering, College of Engineering, University of Iowa, Iowa City, IA, 52242, United States.
Tony Jun HuangDepartment of Mechanical Engineering and Materials Science, Pratt School of Engineering, Duke University, Durham, NC, 27710, United States.
University of Iowa · USDuke University · US

Funding

Development of a digital acoustofluidic system for automating liquid handling in biomedical researchR01GM141055 · NIGMS · DUKE UNIVERSITY · PI HUANG, TONY JUN · 2021 to 2024
$1.9M
AFS/SERS Saliva-based SARS-CoV-2 Earliest Infection and Antibodies DetectionU18TR003778 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HUANG, TONY JUN, KIM, YONG · 2021 to 2022
$1.8M
Integrated Acoustofluidic Plasmonic Molecular Diagnostic System for Detecting MicroRNA BiomarkersR01GM135486 · NIGMS · DUKE UNIVERSITY · PI VO-DINH, TUAN · 2020 to 2023
$1.8M
Enabling Efficient, Fast, Biocompatible Exosome Separation via AcoustofluidicsR01GM132603 · NIGMS · DUKE UNIVERSITY · PI HUANG, TONY JUN · 2019 to 2022
$1.7M
NCATS NIH HHS U18 TR003778NIGMS NIH HHS R01 GM132603NIGMS NIH HHS R01 GM135486NIGMS NIH HHS R01 GM141055
6 · The paper itself

Abstract

COVID-19, an infectious pulmonary disease caused by the SARS-CoV-2 virus, has profoundly impacted the world, motivating researchers across a broad spectrum of academic disciplines to gain a deeper understanding and develop effective therapies to this disease. This article presents an engineering perspective on how microfluidic technologies may address some of the challenges presented by COVID-19 and other pulmonary diseases. In particular, this article highlights urgent needs in pulmonary medicine, with an emphasis on technological innovations in the microfluidic manipulation of particles and fluids, and how these innovations may contribute to the study, diagnosis, and therapy of pulmonary diseases.

Indexed as

COVID-19DiagnosticsMicrofluidic technologyPulmonary diseasesTherapeutics

Identifiers

PMID35103108
PMCPMC8791846
OpenAlexW4210668908

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.